Advertisement

 

 

Risk of endstage liver disease in HIV-viral hepatitis co-infected persons in North America from the early to modern antiretroviral therapy eras.

Risk of endstage liver disease in HIV-viral hepatitis co-infected persons in North America from the early to modern antiretroviral therapy eras.
Author Information (click to view)

Klein MB, Althoff KN, Jing Y, Lau B, Kitahata M, Lo Re V, Kirk GD, Hull M, Kim HN, Sebastiani G, Moodie E, Silverberg MJ, Sterling TR, Thorne JE, Cescon A, Napravnik S, Eron J, Gill MJ, Justice A, Peters MG, Goedert J, Mayor A, Thio CL, Cachay ER, Moore R, ,


Klein MB, Althoff KN, Jing Y, Lau B, Kitahata M, Lo Re V, Kirk GD, Hull M, Kim HN, Sebastiani G, Moodie E, Silverberg MJ, Sterling TR, Thorne JE, Cescon A, Napravnik S, Eron J, Gill MJ, Justice A, Peters MG, Goedert J, Mayor A, Thio CL, Cachay ER, Moore R, , (click to view)

Klein MB, Althoff KN, Jing Y, Lau B, Kitahata M, Lo Re V, Kirk GD, Hull M, Kim HN, Sebastiani G, Moodie E, Silverberg MJ, Sterling TR, Thorne JE, Cescon A, Napravnik S, Eron J, Gill MJ, Justice A, Peters MG, Goedert J, Mayor A, Thio CL, Cachay ER, Moore R, ,

Advertisement
Share on FacebookTweet about this on TwitterShare on LinkedIn

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2016 8 9() pii

Abstract
BACKGROUND
 HIV-infected patients co-infected with Hepatitis B (HBV) and C (HCV) viruses are at increased risk of endstage liver disease (ESLD). Whether modern antiretroviral therapy has reduced ESLD risk is unknown.

METHODS
 Patients from 12 clinical cohorts in US and Canada participating in the North American AIDS Cohort Collaboration on Research and Design that validated ESLD events from Jan 1, 1996 to Dec 31, 2010 were included. ESLD incidence rates and rate ratios according to hepatitis status adjusted for age, sex, race, cohort and time-updated CD4 cell count and HIV RNA were estimated in calendar periods corresponding to major changes in antiretroviral therapy: early (1996-2000), middle (2001-2005), and modern (2006-2010) eras.

RESULTS
 Among 34,119 HIV-infected adults followed for 129,818 person-years, 380 incident ESLD outcomes occurred. ESLD incidence (/1000 person-years) was highest in triply infected (11.57) followed by HBV (8.72) and HCV (6.10) co-infected vs. 1.27 in HIV mono-infected patients. Adjusted incidence rate ratios [95% confidence intervals] comparing the modern to the early antiretroviral era were: 0.95 [0.61-1.47] for HCV, 0.95 [0.40-2.26] for HBV and 1.52 [0.46-5.02] for triply infected patients. Use of antiretrovirals with dual activity against HBV increased over time. However, in the modern era 35% of HBV co-infected patients were not receiving tenofovir. There was little use of HCV therapy.

CONCLUSIONS
 Despite increasing use of antiretrovirals, no clear reduction in ESLD risk was observed over 15 years. Treatment with direct acting antivirals for HCV and wider use of tenofovir-based regimens for HBV should be prioritized for co-infected patients.

Submit a Comment

Your email address will not be published. Required fields are marked *

four × 1 =

[ HIDE/SHOW ]